18q21 rearrangement in diffuse large cell lymphoma: incidence and clinical significance

Kenneth Offit, Prasad R.K. Koduru, Rachel Hollis, Daniel Filippa, Suresh C. Jhanwar, Bayard C. Clarkson, R. S.K. Chaganti

Research output: Contribution to journalArticlepeer-review

88 Scopus citations


Summary. Cytogenetic, molecular genetic and clinical information was collected for 102 cases of diffuse large cell lymphoma (DLCL) ascertained in a diagnostic laboratory over a 3‐year period. Nineteen cases showed evidence of either a t(14;18) or a rearrangement of one of three genomic probes for breakpoints at 18q21. Clinical and histologic evidence of transformation from follicular lymphoma or chronic lymphocytic leukaemia was available in six cases. Except for age, prognostic clinical variables (LDH, stage, extranodal involvement) were similar between the 18q21 rearranged patients and DLCL patients without 18q21 rearrangement. At a median follow‐up in excess of 2 years for both groups, there was no difference in overall survival between the 18q21 rearranged group compared to DLCL patients lacking this genetic abnormality. The median disease‐free survival for the 18q21 rearranged group, however, was significantly shorter and survival in partial remission longer. The propensity for extended survival of the 18q21 rearranged DLCL patients with residual or recurrent disease resembled the clinical behaviour of nodular lymphoma patients with t(14;18). These results suggest that cytogenic or molecular genetic identification of a chromosome 18q21 translocation may be of prognostic significance in the analysis of treatment protocols for patients with DLCL.

Original languageEnglish
Pages (from-to)178-183
Number of pages6
JournalBritish Journal of Haematology
Issue number2
StatePublished - Jun 1989
Externally publishedYes


Dive into the research topics of '18q21 rearrangement in diffuse large cell lymphoma: incidence and clinical significance'. Together they form a unique fingerprint.

Cite this